ArrowMark Colorado Holdings LLC lessened its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 11.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 871,762 shares of the company's stock after selling 114,072 shares during the quarter. HealthEquity accounts for 1.1% of ArrowMark Colorado Holdings LLC's portfolio, making the stock its 27th largest position. ArrowMark Colorado Holdings LLC owned 1.01% of HealthEquity worth $83,646,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of HQY. Arcadia Investment Management Corp MI purchased a new position in shares of HealthEquity during the 4th quarter valued at approximately $26,000. Transce3nd LLC bought a new position in HealthEquity during the 4th quarter valued at $29,000. Smartleaf Asset Management LLC boosted its stake in HealthEquity by 34.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock valued at $37,000 after acquiring an additional 98 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in HealthEquity during the 4th quarter worth $39,000. Finally, UMB Bank n.a. increased its position in shares of HealthEquity by 65.6% in the 4th quarter. UMB Bank n.a. now owns 414 shares of the company's stock worth $40,000 after purchasing an additional 164 shares during the last quarter. Institutional investors and hedge funds own 99.55% of the company's stock.
HealthEquity Stock Performance
HealthEquity stock traded up $0.84 during midday trading on Monday, reaching $91.42. 1,268,796 shares of the stock traded hands, compared to its average volume of 783,180. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $115.59. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.51. The firm has a market cap of $7.91 billion, a price-to-earnings ratio of 83.87, a PEG ratio of 1.60 and a beta of 0.45. The firm has a fifty day moving average price of $89.27 and a two-hundred day moving average price of $96.66.
Analysts Set New Price Targets
HQY has been the subject of a number of research reports. Raymond James upgraded HealthEquity from an "outperform" rating to a "strong-buy" rating and decreased their price target for the stock from $120.00 to $115.00 in a research note on Tuesday, March 25th. Barrington Research reiterated an "outperform" rating and issued a $112.00 target price on shares of HealthEquity in a research report on Friday, April 11th. KeyCorp dropped their price target on HealthEquity from $110.00 to $100.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 16th. The Goldman Sachs Group decreased their price objective on shares of HealthEquity from $107.00 to $94.00 and set a "neutral" rating for the company in a report on Thursday, March 27th. Finally, Wells Fargo & Company boosted their target price on shares of HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $111.75.
Get Our Latest Research Report on HealthEquity
Insider Transactions at HealthEquity
In related news, Director Robert W. Selander sold 5,750 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $111.29, for a total value of $639,917.50. Following the completion of the sale, the director now owns 78,219 shares of the company's stock, valued at $8,704,992.51. This represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael Henry Fiore sold 8,881 shares of the firm's stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $78.26, for a total transaction of $695,027.06. Following the transaction, the executive vice president now directly owns 56,655 shares in the company, valued at approximately $4,433,820.30. The trade was a 13.55 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,381 shares of company stock worth $1,781,432. Company insiders own 2.20% of the company's stock.
HealthEquity Company Profile
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
